Dyax to Present at the Deutsche Bank Health Care Conference
Dyax Corp. (Nasdaq:DYAX), a developer of novel biotherapeutics for unmet medical needs, announced today that Henry E. Blair, Chairman and Chief Executive Officer of Dyax, will present at the Deutsche Bank 32nd Annual Health Care Conference, being held May 2-3 at The Mayflower Hotel in Washington, D.C. Mr. Blair will present a corporate progress report, including an update on the Company’s clinical development programs. The Dyax Corp. presentation is scheduled for Wednesday, May 2 at 10:30 AM (ET).
The Dyax presentation will be webcast live and may be accessed by visiting the Investor Relations section of the company website at www.dyax.com. The 40-minute presentation will also be available on the Dyax website for a limited period of time following the conference.
About Dyax
Dyax is focused on advancing novel biotherapeutics for unmet medical needs, with an emphasis on oncology and inflammatory indications. Dyax utilizes its proprietary drug discovery technology to identify antibody, small protein and peptide compounds for clinical development.
Dyax’s lead product candidate is DX-88, a recombinant small protein that is currently in clinical trials for its therapeutic potential in two separate indications. Dyax has successfully completed three Phase 2 trials and a Phase 3 trial of DX-88 for the treatment of hereditary angioedema (HAE). Dyax initiated its second Phase 3 trial, known as EDEMA4, in April 2007. DX-88 has orphan drug designation in the U.S. and E.U., as well as Fast Track designation in the U.S. for the treatment of acute attacks of HAE.
Additionally, Dyax has successfully completed a Phase 1/2 trial of DX-88 for the prevention of blood loss during on-pump coronary artery bypass graft (CABG) procedures. Dyax is initiating a Phase 2 trial for further development of DX-88 in on-pump cardiothoracic surgery (CTS), including CABG and heart valve replacement or repair procedures.
Dyax identified DX-88 and other compounds in its pipeline using its patented phage display technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. Dyax leverages this technology broadly with over 70 revenue generating licenses and collaborations for therapeutic discovery, as well as in non-core areas such as affinity separations, diagnostic imaging, and research reagents.
Dyax is headquartered in Cambridge, Massachusetts, and has antibody discovery facilities in Liege, Belgium. For online information about Dyax Corp., please visit www.dyax.com.